Latest Ratios: P/E Ratio -1.9x · EV/EBITDA 20.9x · ROE -41.9%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.0B | $1.3B | $2.8B | $3.3B | $2.9B | $4.9B | $3.8B | $3.0B | $4.0B | $2.4B | $1.9B |
| Enterprise Value | $2.8B | $2.1B | $3.6B | $4.0B | $2.8B | $4.9B | $3.7B | $2.9B | $3.9B | $2.4B | $1.8B |
| P/E Ratio → | -1.87 | — | — | — | 58.80 | 80.96 | 63.59 | 49.42 | 63.08 | 55.21 | 51.44 |
| P/S Ratio | 2.28 | 1.42 | 3.08 | 4.02 | 5.42 | 10.55 | 9.00 | 7.13 | 9.93 | 6.78 | 5.82 |
| P/B Ratio | 0.98 | 0.61 | 0.91 | 1.05 | 3.22 | 5.88 | 5.19 | 4.63 | 7.05 | 5.15 | 4.63 |
| P/FCF | — | — | — | — | 65.54 | 90.91 | 60.89 | 60.06 | 81.99 | 53.16 | 88.61 |
| P/OCF | 35.09 | 21.82 | 80.73 | 80.52 | 42.01 | 60.96 | 43.84 | 46.26 | 57.14 | 40.30 | 52.94 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.30 | 3.88 | 4.91 | 5.34 | 10.39 | 8.85 | 7.03 | 9.72 | 6.56 | 5.65 |
| EV / EBITDA | 20.93 | 15.21 | 18.03 | 32.07 | 34.18 | 51.14 | 43.06 | 33.97 | 44.32 | 29.53 | 26.47 |
| EV / EBIT | 300.17 | — | 58.37 | 119.04 | 46.73 | 64.69 | 51.16 | 39.91 | 52.64 | 35.27 | 32.70 |
| EV / FCF | — | — | — | — | 64.52 | 89.55 | 59.84 | 59.21 | 80.26 | 51.47 | 85.99 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.1% | 47.1% | 50.1% | 49.4% | 46.1% | 45.9% | 46.9% | 46.3% | 46.8% | 47.1% | 47.6% |
| Operating Margin | 1.1% | 1.1% | 8.4% | 4.6% | 11.1% | 15.8% | 16.1% | 16.4% | 17.6% | 18.1% | 17.6% |
| Net Profit Margin | -122.1% | -122.1% | -1.0% | -2.8% | 9.2% | 13.0% | 14.2% | 14.5% | 15.9% | 12.2% | 11.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -41.9% | -41.9% | -0.3% | -1.1% | 5.6% | 7.8% | 8.7% | 10.0% | 12.2% | 10.0% | 9.7% |
| ROA | -27.3% | -27.3% | -0.2% | -0.8% | 5.1% | 7.1% | 8.0% | 9.2% | 11.0% | 8.9% | 8.7% |
| ROIC | 0.2% | 0.2% | 1.5% | 1.2% | 5.5% | 7.8% | 8.1% | 9.5% | 12.1% | 13.1% | 13.3% |
| ROCE | 0.2% | 0.2% | 1.8% | 1.4% | 6.6% | 9.2% | 9.6% | 11.0% | 13.1% | 14.2% | 14.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.44 | 0.44 | 0.29 | 0.29 | — | 0.00 | 0.00 | — | — | — | — |
| Debt / EBITDA | 6.76 | 6.76 | 4.56 | 7.13 | — | 0.01 | 0.01 | — | — | — | — |
| Net Debt / Equity | — | 0.38 | 0.23 | 0.23 | -0.05 | -0.09 | -0.09 | -0.07 | -0.15 | -0.16 | -0.14 |
| Net Debt / EBITDA | 5.80 | 5.80 | 3.70 | 5.83 | -0.54 | -0.78 | -0.76 | -0.49 | -0.95 | -0.97 | -0.81 |
| Debt / FCF | — | — | — | — | -1.02 | -1.37 | -1.05 | -0.85 | -1.72 | -1.70 | -2.62 |
| Interest Coverage | -14.85 | -14.85 | 0.84 | 0.61 | 836.21 | 964.97 | — | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.32 | 3.32 | 3.82 | 4.03 | 8.05 | 11.03 | 11.08 | 11.75 | 9.71 | 8.14 | 8.74 |
| Quick Ratio | 2.22 | 2.22 | 2.59 | 3.11 | 6.48 | 9.16 | 9.12 | 9.50 | 7.75 | 6.11 | 6.49 |
| Cash Ratio | 0.74 | 0.74 | 1.11 | 1.69 | 4.90 | 7.11 | 7.09 | 6.99 | 5.45 | 3.99 | 3.77 |
| Asset Turnover | — | 0.26 | 0.20 | 0.18 | 0.53 | 0.51 | 0.52 | 0.60 | 0.64 | 0.68 | 0.71 |
| Inventory Turnover | 2.48 | 2.48 | 2.44 | 3.11 | 2.32 | 2.52 | 2.33 | 2.58 | 2.78 | 2.59 | 2.61 |
| Days Sales Outstanding | — | 62.58 | 68.32 | 68.01 | 69.01 | 71.54 | 73.91 | 72.78 | 72.54 | 69.86 | 76.86 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 1.7% | 1.2% | 1.6% | 2.0% | 1.6% | 1.8% | 1.9% |
| FCF Yield | — | — | — | — | 1.5% | 1.1% | 1.6% | 1.7% | 1.2% | 1.9% | 1.1% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $217M | $216M | $189M | $108M | $107M | $106M | $105M | $104M | $102M | $101M |
Integration-driven margin erosion
According to current market data, NEOG trades at a forward P/E of 25.89, which appears to price in a significant recovery that remains unsupported by the company's recent negative GAAP earnings and the ongoing volatility associated with the 3M Food Safety business integration.
The negative TTM P/E ratio highlights the distortion caused by merger-related accounting charges, rendering traditional valuation metrics less useful for assessing current earning power. Investors should monitor whether the forward multiple is justified by a return to historical margin profiles or if the market is overly optimistic regarding the synergy realization timeline.
As reported in financial statements, NEOG's ROIC has languished near zero, specifically at -0.1% in 2026Q3, indicating that the company is currently failing to generate meaningful returns on its invested capital base following the massive capital deployment for the 3M Food Safety merger.
The collapse in return metrics suggests that the company's asset base is currently underperforming, likely due to the combination of elevated goodwill and the operational drag of integrating a larger business unit. A sustained recovery in ROIC will require both a reduction in the asset base through amortization and a significant improvement in operating margins.
Based on the provided quarterly data, NEOG's cash conversion cycle has expanded to 132 days as of 2026Q3, reflecting significant inefficiencies in inventory management and a potential disconnect between the company's diagnostic consumable production and its ability to convert those sales into cash.
The elevated days inventory outstanding, which reached 130 days in the most recent quarter, suggests that the company may be holding excess stock or struggling with supply chain bottlenecks post-merger. This inefficiency ties up capital that could otherwise be used to deleverage or fund R&D, warranting further investigation into the company's inventory turnover strategy.
As evidenced by the 2026Q3 interest coverage ratio of -0.46, NEOG's ability to service its debt obligations from operating income has become severely compromised, indicating that the company's current earnings are insufficient to cover interest expenses following the debt-heavy 3M Food Safety transaction.
While the reported debt-to-equity ratio of 0.38 suggests moderate leverage, the negative interest coverage ratio is a critical warning sign that the company's operational cash flow is not yet scaling with its debt burden. Investors should monitor whether this is a temporary liquidity squeeze or a structural issue requiring a more aggressive debt reduction plan.
The P/E ratio is frequently misapplied to NEOG, as the company's GAAP earnings are currently distorted by massive non-cash amortization and one-time merger charges, which obscure the underlying cash-generating capacity of the diagnostic business model.
Analysts should instead focus on Adjusted EBITDA or Free Cash Flow to evaluate the company's true performance, as these metrics better reflect the recurring nature of the diagnostic consumable revenue stream. Relying on the P/E ratio in the current environment may lead to an inaccurate assessment of the company's valuation and its potential for long-term compounding.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NEOG stock.
Neogen Corporation's current P/E ratio is -1.9x. The historical average is 38.9x.
Neogen Corporation's current EV/EBITDA is 20.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 23.9x.
Neogen Corporation's return on equity (ROE) is -41.9%. The historical average is 7.9%.
Based on historical data, Neogen Corporation is trading at a P/E of -1.9x. Compare with industry peers and growth rates for a complete picture.
Neogen Corporation has 47.1% gross margin and 1.1% operating margin.
Neogen Corporation's Debt/EBITDA ratio is 6.8x, indicating high leverage. A ratio above 4x may signal elevated financial risk.